Aggregation state and neurotoxic properties of Alzheimer β-amyloid peptide

Current Protein and Peptide Science

Volumn 12, Issue 3, 2011, Pages 235-257

  Mohamed, Amany ^a   Cortez, Leonardo ^a   de Chaves, Elena Posse ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Aggregation imhibition; Alzheimer's disease; Amyloid; Neurodegeneration; Oligomers

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; AZD 103; BETA CYCLODEXTRIN; CAPROSPINOL; CLIOQUINOL; CONGO RED; CURCUMIN; DERMATAN SULFATE; EPIGALLOCATECHIN GALLATE; EXEBRYL 1; GANGLIOSIDE GM1; GINKGO BILOBA EXTRACT; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HOMOTAURINE; INOSITOL; MEPACRINE; METABOTROPIC RECEPTOR 5; MONOMER; N,N BIS(3 HYDROXYPHENYL)PYRIDAZINE 3,6 DIAMINE; NICASTRIN; NOOTROPIC AGENT; OLIGOMER; PYRIDAZINE DERIVATIVE; RS 0406; SEN 1269; THIOFLAVINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACTIVE IMMUNIZATION; ALPHA HELIX; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANTIBODY AFFINITY; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; CALCIUM SIGNALING; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; COGNITIVE DEFECT; COMPETITIVE INHIBITION; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HYDROPHOBICITY; INFRARED SPECTROSCOPY; LONG TERM POTENTIATION; MOLECULAR WEIGHT; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN AGGREGATION; PROTEIN ASSEMBLY; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; PROTEIN STRUCTURE; PROTEIN TERTIARY STRUCTURE; STRUCTURE ANALYSIS; TEA; UNSPECIFIED SIDE EFFECT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; HUMANS; NEURONS; PROTEIN FOLDING; PROTEOSTASIS DEFICIENCIES;

EID: 79959294944     PISSN: 13892037     EISSN: 18755550     Source Type: Journal    
DOI: 10.2174/138920311795860214     Document Type: Article

References (353)

1. Minati, L.; Edginton, T.; Bruzzone, M.G.; Giaccone, G. Current concepts in Alzheimer's disease: a multidisciplinary review. Am. J. Alzheimers Dis. Other Demen., 2009, 24, 95-121.
2. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81, 741-766.
3. Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci., 1991, 12, 383-388.
4. Hardy, J.A.; Higgins, G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science, 1992, 256, 184-185.
5. Selkoe, D.J. The molecular pathology of Alzheimer's disease. Neuron, 1991, 6, 487-498.
6. Hardy, J. The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem., 2009, 110, 1129-1134.
7. Pimplikar, S.W. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int. J. Biochem. Cell Biol., 2009, 41, 1261-1268.
8. Thinakaran, G.; Koo, E.H. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem., 2008, 283, 29615-29619.
9. Vetrivel, K.S.; Thinakaran, G. Amyloidogenic processing of betaamyloid precursor protein in intracellular compartments. Neurology, 2006, 66, S69-S73.
10. Haass, C.; Schlossmacher, M.G.; Hung, A.Y.; Vigo-Pelfrey, C.; Mellon, A.; Ostaszewski, B.L.; Lieberburg, I.; Koo, E.H.; Schenk, D.; Teplow, D. B.; et al. Amyloid beta-peptide is produced by cultured cells during normal metabolism. Nature, 1992, 359, 322-325.
11. Seubert, P.; Vigo-Pelfrey, C.; Esch, F.; Lee, M.; Dovey, H.; Davis, D.; Sinha, S.; Schlossmacher, M.; Whaley, J.; Swindlehurst, C.; et al. Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature, 1992, 359, 325-327.
12. Kawarabayashi, T.; Younkin, L.H.; Saido, T.C.; Shoji, M.; Ashe, K.H.; Younkin, S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci., 2001, 21, 372-381.
13. Selkoe, D.J. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res., 2008, 192, 106-113.
14. Strittmatter, W.J.; Weisgraber, K.H.; Huang, D.Y.; Dong, L.M.; Salvesen, G.S.; Pericak-Vance, M.; Schmechel, D.; Saunders, A.M.; Goldgaber, D.; Roses, A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoformspecific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1993, 90, 8098-8102.
15. Yao, Z.X.; Papadopoulos, V. Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. Faseb. J., 2002, 16, 1677-1679.
16. Narindrasorasak, S.; Lowery, D.; Gonzalez-DeWhitt, P.; Poorman, R.A.; Greenberg, B.; Kisilevsky, R. High affinity interactions between the Alzheimer's beta-amyloid precursor proteins and the basement membrane form of heparan sulfate proteoglycan. J. Biol. Chem., 1991, 266, 12878-12883.
17. Buee, L.; Ding, W.; Anderson, J.P.; Narindrasorasak, S.; Kisilevsky, R.; Boyle, N.J.; Robakis, N.K.; Delacourte, A.; Greenberg, B.; Fillit, H.M. Binding of vascular heparan sulfate proteoglycan to Alzheimer's amyloid precursor protein is mediated in part by the N-terminal region of A4 peptide. Brain Res., 1993, 627, 199-204.
18. Adlard, P.A.; Bush, A.I. Metals and Alzheimer's disease. J. Alzheimers Dis., 2006, 10, 145-163.
19. Bush, A.I.; Pettingell, W.H.; Multhaup, G.; d Paradis, M.; Vonsattel, J.P.; Gusella, J.F.; Beyreuther, K.; Masters, C.L.; Tanzi, R.E. Rapid induction of Alzheimer A beta amyloid formation by zinc. Science, 1994, 265, 1464-1467.
20. Cotman, S.L.; Halfter, W.; Cole, G.J. Agrin binds to beta-amyloid (Abeta), accelerates abeta fibril formation, and is localized to Abeta deposits in Alzheimer's disease brain. Mol. Cell Neurosci., 2000, 15, 183-198.
21. Grabowski, T.J.; Cho, H.S.; Vonsattel, J.P.; Rebeck, G.W.; Greenberg, S.M. Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann. Neurol., 2001, 49, 697-705.
22. Hendriks, L.; van Duijn, C.M.; Cras, P.; Cruts, M.; Van Hul, W.; van Harskamp, F.; Warren, A.; McInnis, M.G.; Antonarakis, S.E.; Martin, J. J.; et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the beta-amyloid precursor protein gene. Nature genetics, 1992, 1, 218-221.
23. Kamino, K.; Orr, H.T.; Payami, H.; Wijsman, E.M.; Alonso, M.E.; Pulst, S.M.; Anderson, L.; O'Dahl, S.; Nemens, E.; White, J. A.; et al. Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am. J. Hum. Genet., 1992, 51, 998-1014.
24. Levy, E.; Carman, M.D.; Fernandez-Madrid, I.J.; Power, M.D.; Lieberburg, I.; van Duinen, S.G.; Bots, G.T.; Luyendijk, W.; Frangione, B. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science, 1990, 248, 1124-1126.
25. McLaurin, J.; Chakrabartty, A. Characterization of the interactions of Alzheimer beta-amyloid peptides with phospholipid membranes. Eur. J. Biochem., 1997, 245, 355-363.
26. Nilsberth, C.; Westlind-Danielsson, A.; Eckman, C.B.; Condron, M.M.; Axelman, K.; Forsell, C.; Stenh, C.; Luthman, J.; Teplow, D.B.; Younkin, S.G.; Naslund, J.; Lannfelt, L. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat. Neurosci., 2001, 4, 887-893.
27. Soto, C.; Kindy, M.S.; Baumann, M.; Frangione, B. Inhibition of Alzheimer's amyloidosis by peptides that prevent beta-sheet conformation. Biochem. Biophys. Res. Commun., 1996, 226, 672-680.
28. Syme, C.D.; Nadal, R.C.; Rigby, S.E.; Viles, J.H. Copper binding to the amyloid-beta (Abeta) peptide associated with Alzheimer's disease: folding, coordination geometry, pH dependence, stoichiometry, and affinity of Abeta-(1-28): insights from a range of complementary spectroscopic techniques. J Biol Chem, 2004, 279, 18169-18177.
29. Tjernberg, L.O.; Naslund, J.; Lindqvist, F.; Johansson, J.; Karlstrom, A.R.; Thyberg, J.; Terenius, L.; Nordstedt, C. Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem, 1996, 271, 8545-8548.
30. Iwatsubo, T.; Odaka, A.; Suzuki, N.; Mizusawa, H.; Nukina, N.; Ihara, Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron, 1994, 13, 45-53.
31. Gravina, S.A.; Ho, L.; Eckman, C.B.; Long, K.E.; Otvos, L. Jr.; Younkin, L.H.; Suzuki, N.; Younkin, S.G. Amyloid beta protein (A beta) in Alzheimer's disease brain. Biochemical and immunocytochemical analysis with antibodies specific for forms ending at A beta 40 or A beta 42(43). J. Biol. Chem., 1995, 270, 7013-7016.
32. Kawai, M.; Kalaria, R.N.; Cras, P.; Siedlak, S.L.; Velasco, M.E.; Shelton, E.R.; Chan, H.W.; Greenberg, B.D.; Perry, G. Degeneration of vascular muscle cells in cerebral amyloid angiopathy of Alzheimer disease. Brain Res., 1993, 623, 142-146.
33. Guntert, A.; Dobeli, H.; Bohrmann, B. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Neuroscience, 2006, 143, 461-475.
34. Hartig, W.; Goldhammer, S.; Bauer, U.; Wegner, F.; Wirths, O.; Bayer, T.A.; Grosche, J. Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. J. Chem. Neuroanat., 2010, 40, 82-92.
35. Joachim, C.L.; Duffy, L.K.; Morris, J.H.; Selkoe, D.J. Protein chemical and immunocytochemical studies of meningovascular beta-amyloid protein in Alzheimer's disease and normal aging. Brain Res., 1988, 474, 100-111.
36. Suzuki, N.; Iwatsubo, T.; Odaka, A.; Ishibashi, Y.; Kitada, C.; Ihara, Y. High tissue content of soluble beta 1-40 is linked to cerebral amyloid angiopathy. Am. J. Pathol., 1994, 145, 452-460.
37. Roher, A.E.; Ball, M.J.; Bhave, S.V.; Wakade, A.R. Beta-amyloid from Alzheimer disease brains inhibits sprouting and survival of sympathetic neurons. Biochem. Biophys. Res. Commun., 1991, 174, 572-579.
38. Saido, T.C.; Iwatsubo, T.; Mann, D.M.; Shimada, H.; Ihara, Y.; Kawashima, S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron, 1995, 14, 457-466.
39. Mori, H.; Takio, K.; Ogawara, M.; Selkoe, D.J. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J. Biol. Chem., 1992, 267, 17082-17086.
40. Miller, D.L.; Papayannopoulos, I.A.; Styles, J.; Bobin, S.A.; Lin, Y.Y.; Biemann, K.; Iqbal, K. Peptide compositions of the cerebrovascular and senile plaque core amyloid deposits of Alzheimer's disease. Arch. Biochem. Biophys., 1993, 301, 41-52.
41. Perry, G.; Cras, P.; Siedlak, S.L.; Tabaton, M.; Kawai, M. Beta protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. Am. J. Pathol., 1992, 140, 283-290.
42. Miravalle, L.; Calero, M.; Takao, M.; Roher, A.E.; Ghetti, B.; Vidal, R. Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques. Biochemistry, 2005, 44, 10810-10821.
43. Sergeant, N.; Bombois, S.; Ghestem, A.; Drobecq, H.; Kostanjevecki, V.; Missiaen, C.; Wattez, A.; David, J.P.; Vanmechelen, E.; Sergheraert, C.; Delacourte, A. Truncated betaamyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach. J. Neurochem., 2003, 85, 1581-1591.
44. Naslund, J.; Schierhorn, A.; Hellman, U.; Lannfelt, L.; Roses, A.D.; Tjernberg, L.O.; Silberring, J.; Gandy, S.E.; Winblad, B.; Greengard, P.; et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. USA, 1994, 91, 8378-8382.
45. Roher, A.E.; Lowenson, J.D.; Clarke, S.; Woods, A.S.; Cotter, R.J.; Gowing, E.; Ball, M.J. beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1993, 90, 10836-10840.
46. Tekirian, T.L.; Saido, T.C.; Markesbery, W.R.; Russell, M.J.; Wekstein, D.R.; Patel, E.; Geddes, J.W. N-terminal heterogeneity of parenchymal and cerebrovascular Abeta deposits. J. Neuropathol. Exp. Neurol., 1998, 57, 76-94.
47. Russo, C.; Saido, T.C.; DeBusk, L.M.; Tabaton, M.; Gambetti, P.; Teller, J.K. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains. FEBS Lett., 1997, 409, 411-416.
48. Saido, T.C.; Yamao-Harigaya, W.; Iwatsubo, T.; Kawashima, S. Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci. Lett., 1996, 215, 173-176.
49. Wirths, O.; Bethge, T.; Marcello, A.; Harmeier, A.; Jawhar, S.; Lucassen, P.J.; Multhaup, G.; Brody, D.L.; Esparza, T.; Ingelsson, M.; Kalimo, H.; Lannfelt, L.; Bayer, T.A. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J. Neural Transm., 2010, 117, 85-96.
50. Harigaya, Y.; Saido, T.C.; Eckman, C.B.; Prada, C.M.; Shoji, M.; Younkin, S.G. Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain. Biochem. Biophys. Res. Commun., 2000, 276, 422-427.
51. Hosoda, R.; Saido, T.C.; Otvos, L. Jr.; Arai, T.; Mann, D.M.; Lee, V.M.; Trojanowski, J.Q.; Iwatsubo, T. Quantification of modified amyloid beta peptides in Alzheimer disease and Down syndrome brains. J. Neuropathol. Exp. Neurol., 1998, 57, 1089-1095.
52. Lalowski, M.; Golabek, A.; Lemere, C.A.; Selkoe, D.J.; Wisniewski, H.M.; Beavis, R.C.; Frangione, B.; Wisniewski, T. The nonamyloidogenic p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J. Biol. Chem., 1996, 271, 33623-33631.
53. Russo, C.; Schettini, G.; Saido, T.C.; Hulette, C.; Lippa, C.; Lannfelt, L.; Ghetti, B.; Gambetti, P.; Tabaton, M.; Teller, J.K. Presenilin-1 mutations in Alzheimer's disease. Nature, 2000, 405, 531-532.
54. Cynis, H.; Scheel, E.; Saido, T.C.; Schilling, S.; Demuth, H.U. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry, 2008, 47, 7405-7413.
55. Schilling, S.; Zeitschel, U.; Hoffmann, T.; Heiser, U.; Francke, M.; Kehlen, A.; Holzer, M.; Hutter-Paier, B.; Prokesch, M.; Windisch, M.; Jagla, W.; Schlenzig, D.; Lindner, C.; Rudolph, T.; Reuter, G.; Cynis, H.; Montag, D.; Demuth, H.U.; Rossner, S. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat. Med., 2008, 14, 1106-1111.
56. Kuo, Y.M.; Webster, S.; Emmerling, M.R.; De Lima, N.; Roher, A.E. Irreversible dimerization/tetramerization and posttranslational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease. Biochim. Biophys. Acta, 1998, 1406, 291-298.
57. He, W.; Barrow, C.J. The A beta 3-pyroglutamyl and 11- pyroglutamyl peptides found in senile plaque have greater betasheet forming and aggregation propensities in vitro than full-length A beta. Biochemistry, 1999, 38, 10871-10877.
58. D'Arrigo, C.; Tabaton, M.; Perico, A. N-terminal truncated pyroglutamyl beta amyloid peptide Abetapy3-42 shows a faster aggregation kinetics than the full-length Abeta1-42. Biopolymers, 2009, 91, 861-873.
59. Schilling, S.; Lauber, T.; Schaupp, M.; Manhart, S.; Scheel, E.; Bohm, G.; Demuth, H.U. On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry, 2006, 45, 12393-12399.
60. De Kimpe, L.; Scheper, W. From alpha to omega with Abeta: targeting the multiple molecular appearances of the pathogenic peptide in Alzheimer's disease. Curr. Med. Chem., 2010, 17, 198-212.
61. Russo, C.; Violani, E.; Salis, S.; Venezia, V.; Dolcini, V.; Damonte, G.; Benatti, U.; D'Arrigo, C.; Patrone, E.; Carlo, P.; Schettini, G. Pyroglutamate-modified amyloid beta-peptides-- AbetaN3(pE)--strongly affect cultured neuron and astrocyte survival. J. Neurochem., 2002, 82, 1480-1489.
62. Piccini, A.; Russo, C.; Gliozzi, A.; Relini, A.; Vitali, A.; Borghi, R.; Giliberto, L.; Armirotti, A.; D'Arrigo, C.; Bachi, A.; Cattaneo, A.; Canale, C.; Torrassa, S.; Saido, T.C.; Markesbery, W.; Gambetti, P.; Tabaton, M. beta-amyloid is different in normal aging and in Alzheimer disease. J. Biol. Chem., 2005, 280, 34186-34192.
63. Tabaton, M.; Nunzi, M.G.; Xue, R.; Usiak, M.; Autilio-Gambetti, L.; Gambetti, P. Soluble amyloid beta-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem. Biophys. Res. Commun., 1994, 200, 1598-1603.
64. McLean, C.A.; Cherny, R.A.; Fraser, F.W.; Fuller, S.J.; Smith, M.J.; Beyreuther, K.; Bush, A.I.; Masters, C.L. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol., 1999, 46, 860-866.
65. Kuo, Y.M.; Emmerling, M.R.; Vigo-Pelfrey, C.; Kasunic, T.C.; Kirkpatrick, J.B.; Murdoch, G.H.; Ball, M.J.; Roher, A.E. Watersoluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem., 1996, 271, 4077-4081.
66. Funato, H.; Enya, M.; Yoshimura, M.; Morishima-Kawashima, M.; Ihara, Y. Presence of sodium dodecyl sulfate-stable amyloid betaprotein dimers in the hippocampus CA1 not exhibiting neurofibrillary tangle formation. Am. J. Pathol., 1999, 155, 23-28.
67. Teller, J.K.; Russo, C.; DeBusk, L.M.; Angelini, G.; Zaccheo, D.; Dagna-Bricarelli, F.; Scartezzini, P.; Bertolini, S.; Mann, D.M.; Tabaton, M.; Gambetti, P. Presence of soluble amyloid betapeptide precedes amyloid plaque formation in Down's syndrome. Nat. Med., 1996, 2, 93-95.
68. van Helmond, Z.; Miners, J.S.; Kehoe, P.G.; Love, S. Oligomeric Abeta in Alzheimer's disease: relationship to plaque and tangle pathology, APOE genotype and cerebral amyloid angiopathy. Brain Pathol., 2010, 20, 468-480.
69. Tabaton, M.; Gambetti, P. Soluble amyloid-beta in the brain: the scarlet pimpernel. J. Alzheimers Dis., 2006, 9, 127-132.
70. Vigo-Pelfrey, C.; Lee, D.; Keim, P.; Lieberburg, I.; Schenk, D.B. Characterization of beta-amyloid peptide from human cerebrospinal fluid. J. Neurochem., 1993, 61, 1965-1968.
71. Tabaton, M.; Piccini, A. Role of water-soluble amyloid-beta in the pathogenesis of Alzheimer's disease. Int. J. Exp. Pathol., 2005, 86, 139-145.
72. Chang, L.; Bakhos, L.; Wang, Z.; Venton, D.L.; Klein, W.L. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J. Mol. Neurosci., 2003, 20, 305-313.
73. Kawarabayashi, T.; Shoji, M.; Younkin, L.H.; Wen-Lang, L.; Dickson, D.W.; Murakami, T.; Matsubara, E.; Abe, K.; Ashe, K.H.; Younkin, S.G. Dimeric amyloid beta protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci., 2004, 24, 3801-3809.
74. Walsh, D.M.; Tseng, B.P.; Rydel, R.E.; Podlisny, M.B.; Selkoe, D.J. The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry, 2000, 39, 10831-10839.
75. Roher, A.E.; Chaney, M.O.; Kuo, Y.M.; Webster, S.D.; Stine, W.B.; Haverkamp, L.J.; Woods, A.S.; Cotter, R.J.; Tuohy, J.M.; Krafft, G.A.; Bonnell, B.S.; Emmerling, M.R. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem., 1996, 271, 20631-20635.
76. Enya, M.; Morishima-Kawashima, M.; Yoshimura, M.; Shinkai, Y.; Kusui, K.; Khan, K.; Games, D.; Schenk, D.; Sugihara, S.; Yamaguchi, H.; Ihara, Y. Appearance of sodium dodecyl sulfatestable amyloid beta-protein (Abeta) dimer in the cortex during aging. Am. J. Pathol., 1999, 154, 271-279.
77. Lambert, M.P.; Viola, K.L.; Chromy, B.A.; Chang, L.; Morgan, T.E.; Yu, J.; Venton, D.L.; Krafft, G.A.; Finch, C.E.; Klein, W.L. Vaccination with soluble Abeta oligomers generates toxicityneutralizing antibodies. J. Neurochem., 2001, 79, 595-605.
78. Gong, Y.; Chang, L.; Viola, K.L.; Lacor, P.N.; Lambert, M.P.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA, 2003, 100, 10417-10422.
79. van Helmond, Z.; Heesom, K.; Love, S. Characterisation of two antibodies to oligomeric Abeta and their use in ELISAs on human brain tissue homogenates. J. Neurosci. Methods, 2009, 176, 206-212.
80. Cleary, J.P.; Walsh, D.M.; Hofmeister, J.J.; Shankar, G.M.; Kuskowski, M.A.; Selkoe, D.J.; Ashe, K.H. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat. Neurosci., 2005, 8, 79-84.
81. Fukumoto, H.; Tokuda, T.; Kasai, T.; Ishigami, N.; Hidaka, H.; Kondo, M.; Allsop, D.; Nakagawa, M. High-molecular-weight beta-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J., 2010, 24, 2716-2726.
82. Amijee, H.; Scopes, D.I. The quest for small molecules as amyloid inhibiting therapies for Alzheimer's disease. J. Alzheimers Dis., 2009, 17, 33-47.
83. Rahimi, F.; Shanmugam, A.; Bitan, G. Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders. Curr. Alzheimer Res., 2008, 5, 319-341.
84. Zhang, S.; Iwata, K.; Lachenmann, M.J.; Peng, J.W.; Li, S.; Stimson, E.R.; Lu, Y.; Felix, A.M.; Maggio, J.E.; Lee, J.P. The Alzheimer's peptide a beta adopts a collapsed coil structure in water. J. Struct. Biol., 2000, 130, 130-141.
85. Lazo, N.D.; Grant, M.A.; Condron, M.C.; Rigby, A.C.; Teplow, D.B. On the nucleation of amyloid beta-protein monomer folding. Protein Sci., 2005, 14, 1581-1596.
86. Grant, M.A.; Lazo, N.D.; Lomakin, A.; Condron, M.M.; Arai, H.; Yamin, G.; Rigby, A.C.; Teplow, D.B. Familial Alzheimer's disease mutations alter the stability of the amyloid beta-protein monomer folding nucleus. Proc. Natl. Acad. Sci. USA, 2007, 104, 16522-16527.
87. Borreguero, J.M.; Urbanc, B.; Lazo, N.D.; Buldyrev, S.V.; Teplow, D.B.; Stanley, H.E. Folding events in the 21-30 region of amyloid beta-protein (Abeta) studied in silico. Proc. Natl. Acad. Sci. USA, 2005, 102, 6015-6020.
88. Murray, M.M.; Krone, M.G.; Bernstein, S.L.; Baumketner, A.; Condron, M.M.; Lazo, N.D.; Teplow, D.B.; Wyttenbach, T.; Shea, J.E.; Bowers, M.T. Amyloid beta-protein: experiment and theory on the 21-30 fragment. J. Phys. Chem. B, 2009, 113, 6041-6046.
89. Krone, M.G.; Baumketner, A.; Bernstein, S.L.; Wyttenbach, T.; Lazo, N.D.; Teplow, D.B.; Bowers, M.T.; Shea, J.E. Effects of familial Alzheimer's disease mutations on the folding nucleation of the amyloid beta-protein. J. Mol. Biol., 2008, 381, 221-228.
90. Yan, Y.; Wang, C. Abeta42 is more rigid than Abeta40 at the C terminus: implications for Abeta aggregation and toxicity. J. Mol. Biol., 2006, 364, 853-862.
91. Stine, W.B. Jr.; Dahlgren, K.N.; Krafft, G.A.; LaDu, M.J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem., 2003, 278, 11612-11622. Epub 12002 Dec 11623.
92. Dahlgren, K.N.; Manelli, A.M.; Stine, W.B. Jr.; Baker, L.K.; Krafft, G.A.; LaDu, M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem., 2002, 277, 32046-32053.
93. Chen, Y.R.; Glabe, C.G. Distinct early folding and aggregation properties of Alzheimer amyloid-beta peptides Abeta40 and Abeta42: stable trimer or tetramer formation by Abeta42. J. Biol. Chem., 2006, 281, 24414-24422.
94. Choo-Smith, L.P.; Garzon-Rodriguez, W.; Glabe, C.G.; Surewicz, W.K. Acceleration of amyloid fibril formation by specific binding of Abeta-(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem., 1997, 272, 22987-22990.
95. Chimon, S.; Ishii, Y. Capturing intermediate structures of Alzheimer's beta-amyloid, Abeta(1-40), by solid-state NMR spectroscopy. J. Am. Chem. Soc., 2005, 127, 13472-13473.
96. Taylor, B.M.; Sarver, R.W.; Fici, G.; Poorman, R.A.; Lutzke, B.S.; Molinari, A.; Kawabe, T.; Kappenman, K.; Buhl, A.E.; Epps, D.E. Spontaneous aggregation and cytotoxicity of the beta-amyloid Abeta1-40: a kinetic model. J. Protein Chem., 2003, 22, 31-40.
97. Shen, C.L.; Murphy, R.M. Solvent effects on self-assembly of betaamyloid peptide. Biophys. J., 1995, 69, 640-651.
98. Lim, K.H.; Collver, H.H.; Le, Y.T.; Nagchowdhuri, P.; Kenney, J.M. Characterizations of distinct amyloidogenic conformations of the Abeta (1-40) and (1-42) peptides. Biochem. Biophys. Res. Commun., 2007, 353, 443-449.
99. Levine, H. 3rd. Soluble multimeric Alzheimer beta(1-40) preamyloid complexes in dilute solution. Neurobiol. Aging, 1995, 16, 755-764.
100. Bitan, G.; Fradinger, E.A.; Spring, S.M.; Teplow, D.B. Neurotoxic protein oligomers--what you see is not always what you get. Amyloid, 2005, 12, 88-95.
101. Bitan, G.; Lomakin, A.; Teplow, D.B. Amyloid beta-protein oligomerization: prenucleation interactions revealed by photoinduced cross-linking of unmodified proteins. J. Biol. Chem., 2001, 276, 35176-35184.
102. Bitan, G.; Kirkitadze, M.D.; Lomakin, A.; Vollers, S.S.; Benedek, G.B.; Teplow, D.B. Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc. Natl. Acad. Sci. USA, 2003, 100, 330-335.
103. Urbanc, B.; Cruz, L.; Yun, S.; Buldyrev, S.V.; Bitan, G.; Teplow, D.B.; Stanley, H.E. In silico study of amyloid beta-protein folding and oligomerization. Proc. Natl. Acad. Sci. USA, 2004, 101, 17345-17350.
104. Bitan, G.; Vollers, S.S.; Teplow, D.B. Elucidation of primary structure elements controlling early amyloid beta-protein oligomerization. J. Biol. Chem., 2003, 278, 34882-34889.
105. Ahmed, M.; Davis, J.; Aucoin, D.; Sato, T.; Ahuja, S.; Aimoto, S.; Elliott, J.I.; Van Nostrand, W.E.; Smith, S.O. Structural conversion of neurotoxic amyloid-beta(1-42) oligomers to fibrils. Nat. Struct. Mol. Biol., 2010, 17, 561-567.
106. Podlisny, M.B.; Ostaszewski, B.L.; Squazzo, S.L.; Koo, E.H.; Rydell, R.E.; Teplow, D.B.; Selkoe, D.J. Aggregation of secreted amyloid beta-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem., 1995, 270, 9564-9570.
107. Walsh, D.M.; Klyubin, I.; Fadeeva, J.V.; Cullen, W.K.; Anwyl, R.; Wolfe, M.S.; Rowan, M.J.; Selkoe, D.J. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 2002, 416, 535-539.
108. Podlisny, M.B.; Walsh, D.M.; Amarante, P.; Ostaszewski, B.L.; Stimson, E.R.; Maggio, J.E.; Teplow, D.B.; Selkoe, D.J. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. Biochemistry, 1998, 37, 3602-3611.
109. Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trommer, B.; Viola, K.L.; Wals, P.; Zhang, C.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA, 1998, 95, 6448-6453.
110. Klein, W.L. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int., 2002, 41, 345-352.
111. Chromy, B.A.; Nowak, R.J.; Lambert, M.P.; Viola, K.L.; Chang, L.; Velasco, P.T.; Jones, B.W.; Fernandez, S.J.; Lacor, P.N.; Horowitz, P.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry, 2003, 42, 12749-12760.
112. Hepler, R.W.; Grimm, K.M.; Nahas, D.D.; Breese, R.; Dodson, E.C.; Acton, P.; Keller, P.M.; Yeager, M.; Wang, H.; Shughrue, P.; Kinney, G.; Joyce, J.G. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry, 2006, 45, 15157-15167.
113. Barghorn, S.; Nimmrich, V.; Striebinger, A.; Krantz, C.; Keller, P.; Janson, B.; Bahr, M.; Schmidt, M.; Bitner, R.S.; Harlan, J.; Barlow, E.; Ebert, U.; Hillen, H. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. J. Neurochem., 2005.
114. Yu, L.; Edalji, R.; Harlan, J.E.; Holzman, T.F.; Lopez, A.P.; Labkovsky, B.; Hillen, H.; Barghorn, S.; Ebert, U.; Richardson, P.L.; Miesbauer, L.; Solomon, L.; Bartley, D.; Walter, K.; Johnson, R.W.; Hajduk, P.J.; Olejniczak, E.T. Structural characterization of a soluble amyloid beta-peptide oligomer. Biochemistry, 2009, 48, 1870-1877.
115. Roychaudhuri, R.; Yang, M.; Hoshi, M.M.; Teplow, D.B. Amyloid beta-protein assembly and Alzheimer disease. J. Biol. Chem., 2009, 284, 4749-4753.
116. Gellermann, G.P.; Byrnes, H.; Striebinger, A.; Ullrich, K.; Mueller, R.; Hillen, H.; Barghorn, S. Abeta-globulomers are formed independently of the fibril pathway. Neurobiol. Dis., 2008, 30, 212-220.
117. Hoshi, M.; Sato, M.; Matsumoto, S.; Noguchi, A.; Yasutake, K.; Yoshida, N.; Sato, K. Spherical aggregates of beta-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta. Proc. Natl. Acad. Sci. USA, 2003, 100, 6370-6375.
118. Noguchi, A.; Matsumura, S.; Dezawa, M.; Tada, M.; Yanazawa, M.; Ito, A.; Akioka, M.; Kikuchi, S.; Sato, M.; Ideno, S.; Noda, M.; Fukunari, A.; Muramatsu, S.; Itokazu, Y.; Sato, K.; Takahashi, H.; Teplow, D.B.; Nabeshima, Y.; Kakita, A.; Imahori, K.; Hoshi, M. Isolation and characterization of patient-derived, toxic, high mass amyloid beta-protein (Abeta) assembly from Alzheimer disease brains. J. Biol. Chem., 2009, 284, 32895-32905.
119. Hartley, D.M.; Walsh, D.M.; Ye, C.P.; Diehl, T.; Vasquez, S.; Vassilev, P.M.; Teplow, D.B.; Selkoe, D.J. Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci., 1999, 19, 8876-8884.
120. Walsh, D.M.; Hartley, D.M.; Kusumoto, Y.; Fezoui, Y.; Condron, M.M.; Lomakin, A.; Benedek, G.B.; Selkoe, D.J.; Teplow, D.B. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem., 1999, 274, 25945-25952.
121. Harper, J.D.; Wong, S.S.; Lieber, C.M.; Lansbury, P.T. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem. Biol., 1997, 4, 119-125.
122. Caughey, B.; Lansbury, P.T. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci., 2003, 26, 267-298.
123. Kayed, R.; Pensalfini, A.; Margol, L.; Sokolov, Y.; Sarsoza, F.; Head, E.; Hall, J.; Glabe, C. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J. Biol. Chem., 2009, 284, 4230-4237.
124. Lashuel, H.A.; Hartley, D.; Petre, B.M.; Walz, T.; Lansbury, P.T.; Jr. Neurodegenerative disease: amyloid pores from pathogenic mutations. Nature, 2002, 418, 291.
125. Lansbury, P.T.; Jr.; Costa, P. R.; Griffiths, J. M.; Simon, E. J.; Auger, M.; Halverson, K. J.; Kocisko, D. A.; Hendsch, Z. S.; Ashburn, T. T.; Spencer, R. G.; et al. Structural model for the beta-amyloid fibril based on interstrand alignment of an antiparallel-sheet comprising a C-terminal peptide. Nat. Struct. Biol., 1995, 2, 990-998.
126. Serpell, L.C.; Fraser, P.E.; Sunde, M. X-ray fiber diffraction of amyloid fibrils. Methods Enzymol., 1999, 309, 526-536.
127. Kelly, J.W. Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure, 1997, 5, 595-600.
128. Goldsbury, C.S.; Wirtz, S.; Muller, S.A.; Sunderji, S.; Wicki, P.; Aebi, U.; Frey, P. Studies on the in vitro assembly of a beta 1-40: implications for the search for a beta fibril formation inhibitors. J. Struct. Biol., 2000, 130, 217-231.
129. Meinhardt, J.; Sachse, C.; Hortschansky, P.; Grigorieff, N.; Fandrich, M. Abeta(1-40) fibril polymorphism implies diverse interaction patterns in amyloid fibrils. J. Mol. Biol., 2009, 386, 869-877.
130. Kodali, R.; Williams, A.D.; Chemuru, S.; Wetzel, R. Abeta(1-40) forms five distinct amyloid structures whose beta-sheet contents and fibril stabilities are correlated. J. Mol. Biol., 2010, 401, 503-517.
131. Sunde, M.; Serpell, L.C.; Bartlam, M.; Fraser, P.E.; Pepys, M.B.; Blake, C.C. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol., 1997, 273, 729-739.
132. Petkova, A.T.; Leapman, R.D.; Guo, Z.; Yau, W.M.; Mattson, M.P.; Tycko, R. Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science, 2005, 307, 262-265.
133. Olofsson, A.; Lindhagen-Persson, M.; Sauer-Eriksson, A.E.; Ohman, A. Amide solvent protection analysis demonstrates that amyloid-beta(1-40) and amyloid-beta(1-42) form different fibrillar structures under identical conditions. Biochem. J., 2007, 404, 63-70.
134. Luhrs, T.; Ritter, C.; Adrian, M.; Riek-Loher, D.; Bohrmann, B.; Dobeli, H.; Schubert, D.; Riek, R. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc. Natl. Acad. Sci. USA, 2005, 102, 17342-17347.
135. Sawaya, M.R.; Sambashivan, S.; Nelson, R.; Ivanova, M.I.; Sievers, S.A.; Apostol, M.I.; Thompson, M.J.; Balbirnie, M.; Wiltzius, J.J.; McFarlane, H.T.; Madsen, A.O.; Riekel, C.; Eisenberg, D. Atomic structures of amyloid cross-beta spines reveal varied steric zippers. Nature, 2007, 447, 453-457.
136. Sachse, C.; Fandrich, M.; Grigorieff, N. Paired beta-sheet structure of an Abeta(1-40) amyloid fibril revealed by electron microscopy. Proc. Natl. Acad. Sci. USA, 2008, 105, 7462-7466.
137. Paravastu, A.K.; Leapman, R.D.; Yau, W.M.; Tycko, R. Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc. Natl. Acad. Sci. USA, 2008, 105, 18349-18354.
138. Caspar, D.L. Inconvenient facts about pathological amyloid fibrils. Proc. Natl. Acad. Sci. USA, 2009, 106, 20555-20556.
139. Jahn, T.R.; Makin, O.S.; Morris, K.L.; Marshall, K.E.; Tian, P.; Sikorski, P.; Serpell, L.C. The common architecture of cross-beta amyloid. J. Mol. Biol., 2010, 395, 717-727.
140. Lomakin, A.; Teplow, D.B.; Kirschner, D.A.; Benedek, G.B. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc. Natl. Acad. Sci. USA, 1997, 94, 7942-7947.
141. Harper, J.D.; Lansbury, P.T.; Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem., 1997, 66, 385-407.
142. Teplow, D.B. Structural and kinetic features of amyloid betaprotein fibrillogenesis. Amyloid, 1998, 5, 121-142.
143. Jarrett, J.T.; Berger, E.P.; Lansbury, P.T; Jr. The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry, 1993, 32, 4693-4697.
144. Jarrett, J.T.; Lansbury, P.T; Jr. Seeding one-dimensional crystallization of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell, 1993, 73, 1055-1058.
145. Lomakin, A.; Chung, D.S.; Benedek, G.B.; Kirschner, D.A.; Teplow, D.B. On the nucleation and growth of amyloid betaprotein fibrils: detection of nuclei and quantitation of rate constants. Proc. Natl. Acad. Sci. USA, 1996, 93, 1125-1129.
146. Kelly, J.W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol., 1998, 8, 101-106.
147. Mastrangelo, I.A.; Ahmed, M.; Sato, T.; Liu, W.; Wang, C.; Hough, P.; Smith, S.O. High-resolution atomic force microscopy of soluble Abeta42 oligomers. J. Mol. Biol., 2006, 358, 106-119.
148. Snyder, S.W.; Ladror, U.S.; Wade, W.S.; Wang, G.T.; Barrett, L.W.; Matayoshi, E.D.; Huffaker, H.J.; Krafft, G.A.; Holzman, T.F. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys. J., 1994, 67, 1216-1228.
149. Kirkitadze, M.D.; Condron, M.M.; Teplow, D.B. Identification and characterization of key kinetic intermediates in amyloid betaprotein fibrillogenesis. J. Mol. Biol., 2001, 312, 1103-1119.
150. Soto, C.; Castano, E.M.; Frangione, B.; Inestrosa, N.C. The alphahelical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation. J. Biol. Chem., 1995, 270, 3063-3067.
151. Necula, M.; Kayed, R.; Milton, S.; Glabe, C.G. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J. Biol. Chem., 2007, 282, 10311-10324.
152. Inouye, H.; Fraser, P.E.; Kirschner, D.A. Structure of betacrystallite assemblies formed by Alzheimer beta-amyloid protein analogues: analysis by x-ray diffraction. Biophys. J., 1993, 64, 502-519.
153. Fraser, P.E.; Nguyen, J.T.; Surewicz, W.K.; Kirschner, D.A. pHdependent structural transitions of Alzheimer amyloid peptides. Biophys. J., 1991, 60, 1190-1201.
154. Evans, K.C.; Berger, E.P.; Cho, C.G.; Weisgraber, K.H.; Lansbury, P.T.; Jr. Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: implications for the pathogenesis and treatment of Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1995, 92, 763-767.
155. McGowan, E.; Pickford, F.; Kim, J.; Onstead, L.; Eriksen, J.; Yu, C.; Skipper, L.; Murphy, M.P.; Beard, J.; Das, P.; Jansen, K.; Delucia, M.; Lin, W.L.; Dolios, G.; Wang, R.; Eckman, C.B.; Dickson, D.W.; Hutton, M.; Hardy, J.; Golde, T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron, 2005, 47, 191-199.
156. Bibl, M.; Mollenhauer, B.; Esselmann, H.; Lewczuk, P.; Klafki, H.W.; Sparbier, K.; Smirnov, A.; Cepek, L.; Trenkwalder, C.; Ruther, E.; Kornhuber, J.; Otto, M.; Wiltfang, J. CSF amyloid-betapeptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain, 2006, 129, 1177-1187.
157. Wiltfang, J.; Esselmann, H.; Bibl, M.; Hull, M.; Hampel, H.; Kessler, H.; Frolich, L.; Schroder, J.; Peters, O.; Jessen, F.; Luckhaus, C.; Perneczky, R.; Jahn, H.; Fiszer, M.; Maler, J.M.; Zimmermann, R.; Bruckmoser, R.; Kornhuber, J.; Lewczuk, P. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J. Neurochem., 2007, 101, 1053-1059.
158. Hasegawa, K.; Yamaguchi, I.; Omata, S.; Gejyo, F.; Naiki, H. Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry, 1999, 38, 15514-15521.
159. Yan, Y.; Wang, C. Abeta40 protects non-toxic Abeta42 monomer from aggregation. J. Mol. Biol., 2007, 369, 909-916.
160. Jan, A.; Gokce, O.; Luthi-Carter, R.; Lashuel, H.A. The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J. Biol. Chem., 2008, 283, 28176-28189.
161. Han, H.; Weinreb, P.H.; Lansbury, P.T.; Jr. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem. Biol., 1995, 2, 163-169.
162. Paravastu, A.K.; Qahwash, I.; Leapman, R.D.; Meredith, S.C.; Tycko, R. Seeded growth of beta-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc. Natl. Acad. Sci. USA, 2009, 106, 7443-7448.
163. Fraser, P.E.; Nguyen, J.T.; McLachlan, D.R.; Abraham, C.R.; Kirschner, D.A. Alpha 1-antichymotrypsin binding to Alzheimer A beta peptides is sequence specific and induces fibril disaggregation in vitro. J. Neurochem., 1993, 61, 298-305.
164. Eriksson, S.; Janciauskiene, S.; Lannfelt, L. Alpha 1- antichymotrypsin regulates Alzheimer beta-amyloid peptide fibril formation. Proc. Natl. Acad. Sci. USA, 1995, 92, 2313-2317.
165. Tennent, G.A.; Lovat, L.B.; Pepys, M.B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc. Natl. Acad. Sci. USA, 1995, 92, 4299-4303.
166. Brunden, K.R.; Richter-Cook, N.J.; Chaturvedi, N.; Frederickson, R.C. pH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans. J. Neurochem., 1993, 61, 2147-2154.
167. Castillo, G.M.; Ngo, C.; Cummings, J.; Wight, T.N.; Snow, A.D. Perlecan binds to the beta-amyloid proteins (A beta) of Alzheimer's disease, accelerates A beta fibril formation, and maintains A beta fibril stability. J. Neurochem., 1997, 69, 2452-2465.
168. Strittmatter, W.J.; Roses, A.D. Apolipoprotein E and Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1995, 92, 4725-4727.
169. Ma, J.; Yee, A.; Brewer, H.B. Jr.; Das, S.; Potter, H. Amyloidassociated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature, 1994, 372, 92-94.
170. Calero, M.; Rostagno, A.; Matsubara, E.; Zlokovic, B.; Frangione, B.; Ghiso, J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc. Res. Tech., 2000, 50, 305-315.
171. Yerbury, J.J.; Poon, S.; Meehan, S.; Thompson, B.; Kumita, J.R.; Dobson, C.M.; Wilson, M.R. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J., 2007, 21, 2312-2322.
172. Stege, G.J.; Renkawek, K.; Overkamp, P.S.; Verschuure, P.; van Rijk, A.F.; Reijnen-Aalbers, A.; Boelens, W.C.; Bosman, G.J.; de Jong, W.W. The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity. Biochem. Biophys. Res. Commun., 1999, 262, 152-156.
173. Oda, T.; Wals, P.; Osterburg, H.H.; Johnson, S.A.; Pasinetti, G.M.; Morgan, T.E.; Rozovsky, I.; Stine, W.B.; Snyder, S.W.; Holzman, T. F.; et al. Clusterin (apoJ) alters the aggregation of amyloid betapeptide (A beta 1-42) and forms slowly sedimenting A beta complexes that cause oxidative stress. Exp. Neurol., 1995, 136, 22-31.
174. Sakono, M.; Zako, T.; Ueda, H.; Yohda, M.; Maeda, M. Formation of highly toxic soluble amyloid beta oligomers by the molecular chaperone prefoldin. FEBS J., 2008, 275, 5982-5993.
175. Wilhelmus, M.M.; Boelens, W.C.; Otte-Holler, I.; Kamps, B.; de Waal, R.M.; Verbeek, M.M. Small heat shock proteins inhibit amyloid-beta protein aggregation and cerebrovascular amyloid-beta protein toxicity. Brain Res., 2006, 1089, 67-78.
176. Hamos, J.E.; Oblas, B.; Pulaski-Salo, D.; Welch, W.J.; Bole, D.G.; Drachman, D.A. Expression of heat shock proteins in Alzheimer's disease. Neurology, 1991, 41, 345-350.
177. Kakimura, J.; Kitamura, Y.; Takata, K.; Umeki, M.; Suzuki, S.; Shibagaki, K.; Taniguchi, T.; Nomura, Y.; Gebicke-Haerter, P.J.; Smith, M.A.; Perry, G.; Shimohama, S. Microglial activation and amyloid-beta clearance induced by exogenous heat-shock proteins. FASEB J., 2002, 16, 601-603.
178. Evans, C.G.; Wisen, S.; Gestwicki, J.E. Heat shock proteins 70 and 90 inhibit early stages of amyloid beta-(1-42) aggregation in vitro. J. Biol. Chem., 2006, 281, 33182-33191.
179. Magrane, J.; Rosen, K.M.; Smith, R.C.; Walsh, K.; Gouras, G.K.; Querfurth, H.W. Intraneuronal beta-amyloid expression downregulates the Akt survival pathway and blunts the stress response. J. Neurosci., 2005, 25, 10960-10969.
180. Arimon, M.; Grimminger, V.; Sanz, F.; Lashuel, H.A. Hsp104 targets multiple intermediates on the amyloid pathway and suppresses the seeding capacity of Abeta fibrils and protofibrils. J. Mol. Biol., 2008, 384, 1157-1173.
181. Sipe, J.D. Amyloidosis. Annu. Rev. Biochem., 1992, 61, 947-975.
182. McLaurin, J.; Franklin, T.; Zhang, X.; Deng, J.; Fraser, P.E. Interactions of Alzheimer amyloid-beta peptides with glycosaminoglycans effects on fibril nucleation and growth. Eur. J. Biochem., 1999, 266, 1101-1110.
183. Gupta-Bansal, R.; Frederickson, R.C.; Brunden, K.R. Proteoglycan-mediated inhibition of A beta proteolysis. A potential cause of senile plaque accumulation. J. Biol. Chem., 1995, 270, 18666-18671.
184. Buee, L.; Ding, W.; Delacourte, A.; Fillit, H. Binding of secreted human neuroblastoma proteoglycans to the Alzheimer's amyloid A4 peptide. Brain Res., 1993, 601, 154-163.
185. Diaz-Nido, J.; Wandosell, F.; Avila, J. Glycosaminoglycans and beta-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides, 2002, 23, 1323-1332.
186. Oddo, S.; Caccamo, A.; Tran, L.; Lambert, M.P.; Glabe, C.G.; Klein, W.L.; LaFerla, F.M. Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J. Biol. Chem., 2006, 281, 1599-1604.
187. Takahashi, R.H.; Almeida, C.G.; Kearney, P.F.; Yu, F.; Lin, M.T.; Milner, T.A.; Gouras, G.K. Oligomerization of Alzheimer's betaamyloid within processes and synapses of cultured neurons and brain. J. Neurosci., 2004, 24, 3592-3599.
188. Hu, X.; Crick, S.L.; Bu, G.; Frieden, C.; Pappu, R.V.; Lee, J.M. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc. Natl. Acad. Sci. USA, 2009, 106, 20324-20329.
189. Matsuzaki, K.; Kato, K.; Yanagisawa, K. Abeta polymerization through interaction with membrane gangliosides. Biochim. Biophys. Acta, 2010, 1801, 868-877.
190. Yanagisawa, K.; Odaka, A.; Suzuki, N.; Ihara, Y. GM1 ganglioside-bound amyloid beta-protein (A beta): a possible form of preamyloid in Alzheimer's disease. Nat. Med., 1995, 1, 1062-1066.
191. Yanagisawa, K. GM1 ganglioside and the seeding of amyloid in Alzheimer's disease: endogenous seed for Alzheimer amyloid. Neuroscientist, 2005, 11, 250-260.
192. Wakabayashi, M.; Okada, T.; Kozutsumi, Y.; Matsuzaki, K. GM1 ganglioside-mediated accumulation of amyloid beta-protein on cell membranes. Biochem. Biophys. Res. Commun., 2005, 328, 1019-1023.
193. Wakabayashi, M.; Matsuzaki, K. Formation of amyloids by Abeta- (1-42) on NGF-differentiated PC12 cells: roles of gangliosides and cholesterol. J. Mol. Biol., 2007, 371, 924-933.
194. Hayashi, H.; Kimura, N.; Yamaguchi, H.; Hasegawa, K.; Yokoseki, T.; Shibata, M.; Yamamoto, N.; Michikawa, M.; Yoshikawa, Y.; Terao, K.; Matsuzaki, K.; Lemere, C.A.; Selkoe, D.J.; Naiki, H.; Yanagisawa, K. A seed for Alzheimer amyloid in the brain. J. Neurosci., 2004, 24, 4894-4902.
195. Yamamoto, N.; Yokoseki, T.; Shibata, M.; Yamaguchi, H.; Yanagisawa, K. Suppression of Abeta deposition in brain by peripheral administration of Fab fragments of anti-seed antibody. Biochem. Biophys. Res. Commun., 2005, 335, 45-47.
196. Yamamoto, N.; Fukata, Y.; Fukata, M.; Yanagisawa, K. GM1- ganglioside-induced Abeta assembly on synaptic membranes of cultured neurons. Biochim. Biophys. Acta, 2007, 1768, 1128-1137.
197. Kakio, A.; Nishimoto, S.; Yanagisawa, K.; Kozutsumi, Y.; Matsuzaki, K. Interactions of amyloid beta-protein with various gangliosides in raft-like membranes: importance of GM1 ganglioside-bound form as an endogenous seed for Alzheimer amyloid. Biochemistry, 2002, 41, 7385-7390.
198. Oikawa, N.; Yamaguchi, H.; Ogino, K.; Taki, T.; Yuyama, K.; Yamamoto, N.; Shin, R.W.; Furukawa, K.; Yanagisawa, K. Gangliosides determine the amyloid pathology of Alzheimer's disease. Neuroreport, 2009, 20, 1043-1046.
199. Yamamoto, N.; Van Nostrand, W.E.; Yanagisawa, K. Further evidence of local ganglioside-dependent amyloid beta-protein assembly in brain. Neuroreport, 2006, 17, 1735-1737.
200. Simons, K.; Toomre, D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol., 2000, 1, 31-39.
201. Molander-Melin, M.; Blennow, K.; Bogdanovic, N.; Dellheden, B.; Mansson, J.E.; Fredman, P. Structural membrane alterations in Alzheimer brains found to be associated with regional disease development; increased density of gangliosides GM1 and GM2 and loss of cholesterol in detergent-resistant membrane domains. J. Neurochem., 2005, 92, 171-182.
202. Yamamoto, N.; Igbabvoa, U.; Shimada, Y.; Ohno-Iwashita, Y.; Kobayashi, M.; Wood, W.G.; Fujita, S.C.; Yanagisawa, K. Accelerated Abeta aggregation in the presence of GM1-ganglioside-accumulated synaptosomes of aged apoE4-knock-in mouse brain. FEBS Lett., 2004, 569, 135-139.
203. Kakio, A.; Nishimoto, S.I.; Yanagisawa, K.; Kozutsumi, Y.; Matsuzaki, K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J. Biol. Chem., 2001, 276, 24985-24990.
204. Yamamoto, N.; Matsubara, T.; Sato, T.; Yanagisawa, K. Agedependent high-density clustering of GM1 ganglioside at presynaptic neuritic terminals promotes amyloid beta-protein fibrillogenesis. Biochim. Biophys. Acta, 2008, 1778, 2717-2726.
205. Fagan, A.M.; Watson, M.; Parsadanian, M.; Bales, K.R.; Paul, S.M.; Holtzman, D.M. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis., 2002, 9, 305-318.
206. Gylys, K.H.; Fein, J.A.; Yang, F.; Miller, C.A.; Cole, G.M. Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex. Neurobiol. Aging, 2007, 28, 8-17.
207. Probst, A.; Langui, D.; Ipsen, S.; Robakis, N.; Ulrich, J. Deposition of beta/A4 protein along neuronal plasma membranes in diffuse senile plaques. Acta Neuropathol., 1991, 83, 21-29.
208. Igbavboa, U.; Avdulov, N.A.; Schroeder, F.; Wood, W.G. Increasing age alters transbilayer fluidity and cholesterol asymmetry in synaptic plasma membranes of mice. J. Neurochem., 1996, 66, 1717-1725.
209. Hayashi, H.; Igbavboa, U.; Hamanaka, H.; Kobayashi, M.; Fujita, S.C.; Wood, W.G.; Yanagisawa, K. Cholesterol is increased in the exofacial leaflet of synaptic plasma membranes of human apolipoprotein E4 knock-in mice. Neuroreport, 2002, 13, 383-386.
210. Yuyama, K.; Yanagisawa, K. Late endocytic dysfunction as a putative cause of amyloid fibril formation in Alzheimer's disease. J. Neurochem., 2009, 109, 1250-1260.
211. Matsuzaki, K.; Horikiri, C. Interactions of amyloid beta-peptide (1-40) with ganglioside-containing membranes. Biochemistry, 1999, 38, 4137-4142.
212. Kakio, A.; Nishimoto, S.; Kozutsumi, Y.; Matsuzaki, K. Formation of a membrane-active form of amyloid beta-protein in raft-like model membranes. Biochem. Biophys. Res. Commun., 2003, 303, 514-518.
213. Kakio, A.; Yano, Y.; Takai, D.; Kuroda, Y.; Matsumoto, O.; Kozutsumi, Y.; Matsuzaki, K. Interaction between amyloid betaprotein aggregates and membranes. J. Pept. Sci., 2004, 10, 612-621.
214. Okada, T.; Ikeda, K.; Wakabayashi, M.; Ogawa, M.; Matsuzaki, K. Formation of toxic Abeta(1-40) fibrils on GM1 gangliosidecontaining membranes mimicking lipid rafts: polymorphisms in Abeta(1-40) fibrils. J. Mol. Biol., 2008, 382, 1066-1074.
215. Okada, T.; Wakabayashi, M.; Ikeda, K.; Matsuzaki, K. Formation of toxic fibrils of Alzheimer's amyloid beta-protein-(1-40) by monosialoganglioside GM1, a neuronal membrane component. J. Mol. Biol., 2007, 371, 481-489.
216. Matsuzaki, K. Physicochemical interactions of amyloid betapeptide with lipid bilayers. Biochim. Biophys. Acta, 2007, 1768, 1935-1942.
217. Davies, C.A.; Mann, D.M.; Sumpter, P.Q.; Yates, P.O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci., 1987, 78, 151-164.
218. Esiri, M.M.; Pearson, R.C.; Steele, J.E.; Bowen, D.M.; Powell, T.P. A quantitative study of the neurofibrillary tangles and the choline acetyltransferase activity in the cerebral cortex and the amygdala in Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry, 1990, 53, 161-165.
219. Pearson, R.C.; Esiri, M.M.; Hiorns, R.W.; Wilcock, G.K.; Powell, T.P. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc. Natl. Acad. Sci. USA, 1985, 82, 4531-4534.
220. Rodriguez, J.J.; Olabarria, M.; Chvatal, A.; Verkhratsky, A. Astroglia in dementia and Alzheimer's disease. Cell Death Differ., 2009, 16, 378-385.
221. Cameron, B.; Landreth, G.E. Inflammation, microglia, and Alzheimer's disease. Neurobiol. Dis., 2010, 37, 503-509.
222. Terry, R.D.; Masliah, E.; Salmon, D.P.; Butters, N.; DeTeresa, R.; Hill, R.; Hansen, L.A.; Katzman, R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 1991, 30, 572-580.
223. Parihar, M.S.; Hemnani, T. Alzheimer's disease pathogenesis and therapeutic interventions. J. Clin. Neurosci., 2004, 11, 456-467.
224. Whitehouse, P.J.; Price, D.L.; Struble, R.G.; Clark, A.W.; Coyle, J.T.; Delon, M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science, 1982, 215, 1237-1239.
225. Perry, E.K.; Tomlinson, B.E.; Blessed, G.; Bergmann, K.; Gibson, P.H.; Perry, R.H. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br. Med. J., 1978, 2, 1457-1459.
226. Auld, D.S.; Kornecook, T.J.; Bastianetto, S.; Quirion, R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol., 2002, 68, 209-245.
227. Small, D.H.; Mok, S.S.; Bornstein, J.C. Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci., 2001, 2, 595-598.
228. Coleman, P.D. What's Next? Neurobiol. Aging, 2010.
229. Onorato, M.; Mulvihill, P.; Connolly, J.; Galloway, P.; Whitehouse, P.; Perry, G. Alteration of neuritic cytoarchitecture in Alzheimer disease. Prog. Clin. Biol. Res., 1989, 317, 781-789.
230. Coleman, P.D.; Yao, P.J. Synaptic slaughter in Alzheimer's disease. Neurobiol. Aging, 2003, 24, 1023-1027.
231. Scheff, S.W.; Price, D.A. Synaptic pathology in Alzheimer's disease: a review of ultrastructural studies. Neurobiol. Aging, 2003, 24, 1029-1046.
232. Oddo, S.; Caccamo, A.; Shepherd, J.D.; Murphy, M.P.; Golde, T.E.; Kayed, R.; Metherate, R.; Mattson, M.P.; Akbari, Y.; LaFerla, F.M. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 2003, 39, 409-421.
233. DeKosky, S.T.; Scheff, S.W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol., 1990, 27, 457-464.
234. Reddy, P.H.; Mani, G.; Park, B.S.; Jacques, J.; Murdoch, G.; Whetsell, Jr W.; Kaye, J.; Manczak, M. Differential loss of synaptic proteins in Alzheimer's disease: implications for synaptic dysfunction. J. Alzheimers Dis., 2005, 7, 103-117; discussion 173-180.
235. Scheff, S.W.; Price, D.A.; Schmitt, F.A.; DeKosky, S.T.; Mufson, E.J. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology, 2007, 68, 1501-1508.
236. Scheff, S.W.; Price, D.A.; Schmitt, F.A.; Mufson, E.J. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging, 2006, 27, 1372-1384.
237. Vickers, J.C.; Chin, D.; Edwards, A.M.; Sampson, V.; Harper, C.; Morrison, J. Dystrophic neurite formation associated with agerelated beta amyloid deposition in the neocortex: clues to the genesis of neurofibrillary pathology. Exp. Neurol., 1996, 141, 1-11.
238. Stahl, R.; Dietrich, O.; Teipel, S.; Hampel, H.; Reiser, M.F.; Schoenberg, S.O. [Assessment of axonal degeneration on Alzheimer's disease with diffusion tensor MRI]. Radiologe, 2003, 43, 566-575.
239. Probst, A.; Langui, D.; Ulrich, J. Alzheimer's disease: a description of the structural lesions. Brain Pathol., 1991, 1, 229-239.
240. Bian, F.; Nath, R.; Sobocinski, G.; Booher, R.N.; Lipinski, W.J.; Callahan, M.J.; Pack, A.; Wang, K.K.; Walker, L.C. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J. Comp. Neurol., 2002, 446, 257-266.
241. Stokin, G.B.; Lillo, C.; Falzone, T.L.; Brusch, R.G.; Rockenstein, E.; Mount, S.L.; Raman, R.; Davies, P.; Masliah, E.; Williams, D.S.; Goldstein, L.S. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science, 2005, 307, 1282-1288.
242. Brendza, R.P.; Bacskai, B.J.; Cirrito, J.R.; Simmons, K.A.; Skoch, J.M.; Klunk, W.E.; Mathis, C.A.; Bales, K.R.; Paul, S.M.; Hyman, B.T.; Holtzman, D.M. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest., 2005, 115, 428-433.
243. Lombardo, J.A.; Stern, E.A.; McLellan, M.E.; Kajdasz, S.T.; Hickey, G.A.; Bacskai, B.J.; Hyman, B.T. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci, 2003, 23, 10879-10883.
244. Amstrong, R.A. The spatial patterns of beta/A4 deposit subtypes in Down's syndrome. Acta Neuropathol. (Berl.), 1994, 88, 353-358.
245. Jacobs, R.W.; Duong, T.; Scheibel, A.B. Immunohistochemical analysis of the basal forebrain in Alzheimer's disease. Mol. Chem. Neuropathol., 1992, 17, 1-20.
246. Ivins, K.J.; Bui, E.T.; Cotman, C.W. Beta-amyloid induces local neurite degeneration in cultured hippocampal neurons: evidence for neuritic apoptosis. Neurobiol. Dis., 1998, 5, 365-378.
247. Paradis, E.; Douillard, H.; Koutroumanis, M.; Goodyer, C.; LeBlanc, A. Amyloid beta peptide of Alzheimer's disease downregulates Bcl-2 and upregulates bax expression in human neurons. J. Neurosci., 1996, 16, 7533-7539.
248. Song, M.S.; Saavedra, L.; de Chaves, E.I. Apoptosis is secondary to non-apoptotic axonal degeneration in neurons exposed to Abeta in distal axons. Neurobiol. Aging, 2006, 27, 1224-1238.
249. Harkany, T.; Abraham, I.; Timmerman, W.; Laskay, G.; Toth, B.; Sasvari, M.; Konya, C.; Sebens, J.B.; Korf, J.; Nyakas, C.; Zarandi, M.; Soos, K.; Penke, B.; Luiten, P.G. beta-amyloid neurotoxicity is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus basalis. Eur. J. Neurosci., 2000, 12, 2735-2745.
250. Coleman, M.P.; Ribchester, R.R. Programmed axon death, synaptic dysfunction and the ubiquitin proteasome system. Curr. Drug Targets CNS Neurol. Disord., 2004, 3, 227-238.
251. Knowles, R.B.; Wyart, C.; Buldyrev, S.V.; Cruz, L.; Urbanc, B.; Hasselmo, M.E.; Stanley, H.E.; Hyman, B.T. Plaque-induced neurite abnormalities: implications for disruption of neural networks in Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 1999, 96, 5274-5279.
252. Loo, D.T.; Copani, A.; Pike, C.J.; Whittemore, E.R.; Walencewicz, A.J.; Cotman, C.W. Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc. Natl. Acad. Sci. USA, 1993, 90, 7951-7955.
253. Lorenzo, A.; Yankner, B.A. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl. Acad. Sci. USA, 1994, 91, 12243-12247.
254. Pike, C.J.; Burdick, D.; Walencewicz, A.J.; Glabe, C.G.; Cotman, C.W. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci., 1993, 13, 1676-1687.
255. Howlett, D.R.; Jennings, K.H.; Lee, D.C.; Clark, M.S.; Brown, F.; Wetzel, R.; Wood, S.J.; Camilleri, P.; Roberts, G.W. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration, 1995, 4, 23-32.
256. Spires, T.L.; Meyer-Luehmann, M.; Stern, E.A.; McLean, P.J.; Skoch, J.; Nguyen, P.T.; Bacskai, B.J.; Hyman, B.T. Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci., 2005, 25, 7278-7287.
257. Meyer-Luehmann, M.; Spires-Jones, T.L.; Prada, C.; Garcia- Alloza, M.; de Calignon, A.; Rozkalne, A.; Koenigsknecht-Talboo, J.; Holtzman, D.M.; Bacskai, B.J.; Hyman, B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature, 2008, 451, 720-724.
258. Lesne, S.; Koh, M.T.; Kotilinek, L.; Kayed, R.; Glabe, C.G.; Yang, A.; Gallagher, M.; Ashe, K.H. A specific amyloid-beta protein assembly in the brain impairs memory. Nature, 2006, 440, 352-357.
259. Lesne, S.; Kotilinek, L.; Ashe, K.H. Plaque-bearing mice with reduced levels of oligomeric amyloid-beta assemblies have intact memory function. Neuroscience, 2008, 151, 745-749.
260. Galvan, V.; Gorostiza, O.F.; Banwait, S.; Ataie, M.; Logvinova, A.V.; Sitaraman, S.; Carlson, E.; Sagi, S.A.; Chevallier, N.; Jin, K.; Greenberg, D.A.; Bredesen, D.E. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc. Natl. Acad. Sci. USA, 2006, 103, 7130-7135.
261. Hsia, A.Y.; Masliah, E.; McConlogue, L.; Yu, G.Q.; Tatsuno, G.; Hu, K.; Kholodenko, D.; Malenka, R.C.; Nicoll, R.A.; Mucke, L. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. Proc. Natl. Acad. Sci. USA, 1999, 96, 3228-3233.
262. Moechars, D.; Dewachter, I.; Lorent, K.; Reverse, D.; Baekelandt, V.; Naidu, A.; Tesseur, I.; Spittaels, K.; Haute, C.V.; Checler, F.; Godaux, E.; Cordell, B.; Van Leuven, F. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem., 1999, 274, 6483-6492.
263. Mucke, L.; Masliah, E.; Yu, G.Q.; Mallory, M.; Rockenstein, E.M.; Tatsuno, G.; Hu, K.; Kholodenko, D.; Johnson-Wood, K.; McConlogue, L. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci., 2000, 20, 4050-4058.
264. Jacobsen, J.S.; Wu, C.C.; Redwine, J.M.; Comery, T.A.; Arias, R.; Bowlby, M.; Martone, R.; Morrison, J.H.; Pangalos, M.N.; Reinhart, P.H.; Bloom, F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2006, 103, 5161-5166.
265. Lemere, C.A.; Blusztajn, J.K.; Yamaguchi, H.; Wisniewski, T.; Saido, T.C.; Selkoe, D.J. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol. Dis., 1996, 3, 16-32.
266. Villemagne, V.L.; Pike, K.E.; Darby, D.; Maruff, P.; Savage, G.; Ng, S.; Ackermann, U.; Cowie, T.F.; Currie, J.; Chan, S.G.; Jones, G.; Tochon-Danguy, H.; O'Keefe, G.; Masters, C.L.; Rowe, C.C. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia, 2008, 46, 1688-1697.
267. Nordberg, A. Amyloid plaque imaging in vivo: current achievement and future prospects. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35 Suppl 1, S46-50.
268. Holmes, C.; Boche, D.; Wilkinson, D.; Yadegarfar, G.; Hopkins, V.; Bayer, A.; Jones, R.W.; Bullock, R.; Love, S.; Neal, J.W.; Zotova, E.; Nicoll, J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, 2008, 372, 216-223.
269. Hartley, D.M.; Zhao, C.; Speier, A.C.; Woodard, G.A.; Li, S.; Li, Z.; Walz, T. Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit longterm potentiation. J. Biol. Chem., 2008, 283, 16790-16800.
270. Martins, I.C.; Kuperstein, I.; Wilkinson, H.; Maes, E.; Vanbrabant, M.; Jonckheere, W.; Van Gelder, P.; Hartmann, D.; D'Hooge, R.; De Strooper, B.; Schymkowitz, J.; Rousseau, F. Lipids revert inert Abeta amyloid fibrils to neurotoxic protofibrils that affect learning in mice. EMBO J., 2008, 27, 224-233.
271. Pitschke, M.; Prior, R.; Haupt, M.; Riesner, D. Detection of single amyloid beta-protein aggregates in the cerebrospinal fluid of Alzheimer's patients by fluorescence correlation spectroscopy. Nat. Med., 1998, 4, 832-834.
272. Lue, L.F.; Kuo, Y.M.; Roher, A.E.; Brachova, L.; Shen, Y.; Sue, L.; Beach, T.; Kurth, J.H.; Rydel, R.E.; Rogers, J. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol., 1999, 155, 853-862.
273. Gouras, G.K.; Tsai, J.; Naslund, J.; Vincent, B.; Edgar, M.; Checler, F.; Greenfield, J.P.; Haroutunian, V.; Buxbaum, J.D.; Xu, H.; Greengard, P.; Relkin, N.R. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol., 2000, 156, 15-20.
274. Naslund, J.; Haroutunian, V.; Mohs, R.; Davis, K.L.; Davies, P.; Greengard, P.; Buxbaum, J.D. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA, 2000, 283, 1571-1577.
275. Tomiyama, T.; Matsuyama, S.; Iso, H.; Umeda, T.; Takuma, H.; Ohnishi, K.; Ishibashi, K.; Teraoka, R.; Sakama, N.; Yamashita, T.; Nishitsuji, K.; Ito, K.; Shimada, H.; Lambert, M.P.; Klein, W.L.; Mori, H. A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J. Neurosci., 2010, 30, 4845-4856.
276. Shankar, G.M.; Leissring, M.A.; Adame, A.; Sun, X.; Spooner, E.; Masliah, E.; Selkoe, D.J.; Lemere, C.A.; Walsh, D.M. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol. Dis., 2009, 36, 293-302.
277. Kokubo, H.; Saido, T.C.; Iwata, N.; Helms, J.B.; Shinohara, R.; Yamaguchi, H. Part of membrane-bound Abeta exists in rafts within senile plaques in Tg2576 mouse brain. Neurobiol. Aging, 2005, 26, 409-418.
278. Kokubo, H.; Kayed, R.; Glabe, C.G.; Yamaguchi, H. Soluble Abeta oligomers ultrastructurally localize to cell processes and might be related to synaptic dysfunction in Alzheimer's disease brain. Brain Res., 2005, 1031, 222-228.
279. Lacor, P.N.; Buniel, M.C.; Chang, L.; Fernandez, S.J.; Gong, Y.; Viola, K.L.; Lambert, M.P.; Velasco, P.T.; Bigio, E.H.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Synaptic targeting by Alzheimer'srelated amyloid beta oligomers. J. Neurosci., 2004, 24, 10191-10200.
280. Koffie, R.M.; Meyer-Luehmann, M.; Hashimoto, T.; Adams, K.W.; Mielke, M.L.; Garcia-Alloza, M.; Micheva, K.D.; Smith, S.J.; Kim, M.L.; Lee, V.M.; Hyman, B.T.; Spires-Jones, T.L. Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. USA, 2009, 106, 4012-4017.
281. Lambert, M.P.; Barlow, A.K.; Chromy, B.A.; Edwards, C.; Freed, R.; Liosatos, M.; Morgan, T.E.; Rozovsky, I.; Trommer, B.; Viola, K.L.; Wals, P.; Zhang, C.; Finch, C.E.; Krafft, G.A.; Klein, W.L. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA, 1998, 95, 6448-6453.
282. Wang, H.W.; Pasternak, J.F.; Kuo, H.; Ristic, H.; Lambert, M.P.; Chromy, B.; Viola, K.L.; Klein, W.L.; Stine, W.B.; Krafft, G.A.; Trommer, B.L. Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. Brain Res., 2002, 924, 133-140.
283. De Felice, F.G.; Wu, D.; Lambert, M.P.; Fernandez, S.J.; Velasco, P.T.; Lacor, P.N.; Bigio, E.H.; Jerecic, J.; Acton, P.J.; Shughrue, P.J.; Chen-Dodson, E.; Kinney, G.G.; Klein, W.L. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by A beta oligomers. Neurobiol. Aging, 2008, 29, 1334-1347.
284. Kayed, R.; Head, E.; Thompson, J.L.; McIntire, T.M.; Milton, S.C.; Cotman, C.W.; Glabe, C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science, 2003, 300, 486-489.
285. Georganopoulou, D.G.; Chang, L.; Nam, J.M.; Thaxton, C.S.; Mufson, E.J.; Klein, W.L.; Mirkin, C.A. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2005, 102, 2273-2276.
286. Lacor, P.N.; Buniel, M.C.; Furlow, P.W.; Clemente, A.S.; Velasco, P.T.; Wood, M.; Viola, K.L.; Klein, W.L. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci., 2007, 27, 796-807.
287. Renner, M.; Lacor, P.N.; Velasco, P.T.; Xu, J.; Contractor, A.; Klein, W.L.; Triller, A. Deleterious effects of amyloid beta oligomers acting as an extracellular scaffold for mGluR5. Neuron, 2010, 66, 739-754.
288. Standridge, J.B. Current status and future promise of pharmacotherapeutic strategies for Alzheimer's disease. J. Am. Med. Dir. Assoc., 2006, 7, S46-51, 45.
289. Krafft, G.A.; Klein, W.L. ADDLs and the signaling web that leads to Alzheimer's disease. Neuropharmacology, 2010.
290. Poling, A.; Morgan-Paisley, K.; Panos, J.J.; Kim, E.M.; O'Hare, E.; Cleary, J.P.; Lesne, S.; Ashe, K.H.; Porritt, M.; Baker, L.E. Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures. Behav. Brain Res., 2008, 193, 230-234.
291. Townsend, M.; Shankar, G.M.; Mehta, T.; Walsh, D.M.; Selkoe, D.J. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J. Physiol., 2006, 572, 477-492.
292. Shankar, G.M.; Bloodgood, B.L.; Townsend, M.; Walsh, D.M.; Selkoe, D.J.; Sabatini, B.L. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci., 2007, 27, 2866-2875.
293. Billings, L.M.; Green, K.N.; McGaugh, J.L.; LaFerla, F.M. Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J. Neurosci., 2007, 27, 751-761.
294. Shankar, G.M.; Li, S.; Mehta, T.H.; Garcia-Munoz, A.; Shepardson, N.E.; Smith, I.; Brett, F.M.; Farrell, M.A.; Rowan, M.J.; Lemere, C.A.; Regan, C.M.; Walsh, D.M.; Sabatini, B.L.; Selkoe, D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med., 2008, 14, 837-842.
295. Klyubin, I.; Betts, V.; Welzel, A.T.; Blennow, K.; Zetterberg, H.; Wallin, A.; Lemere, C.A.; Cullen, W.K.; Peng, Y.; Wisniewski, T.; Selkoe, D.J.; Anwyl, R.; Walsh, D.M.; Rowan, M.J. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci., 2008, 28, 4231-4237.
296. Citron, M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov., 2010, 9, 387-398.
297. Tanzi, R.E.; Moir, R.D.; Wagner, S.L. Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron, 2004, 43, 605-608.
298. Kanemitsu, H.; Tomiyama, T.; Mori, H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci. Lett., 2003, 350, 113-116.
299. Cheng, I.H.; Scearce-Levie, K.; Legleiter, J.; Palop, J.J.; Gerstein, H.; Bien-Ly, N.; Puolivali, J.; Lesne, S.; Ashe, K.H.; Muchowski, P.J.; Mucke, L. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J. Biol. Chem., 2007, 282, 23818-23828.
300. Gervais, F.; Paquette, J.; Morissette, C.; Krzywkowski, P.; Yu, M.; Azzi, M.; Lacombe, D.; Kong, X.; Aman, A.; Laurin, J.; Szarek, W.A.; Tremblay, P. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol. Aging, 2007, 28, 537-547.
301. Sciarretta, K.L.; Gordon, D.J.; Meredith, S.C. Peptide-based inhibitors of amyloid assembly. Methods Enzymol., 2006, 413, 273-312.
302. Tjernberg, L.O.; Lilliehook, C.; Callaway, D.J.; Naslund, J.; Hahne, S.; Thyberg, J.; Terenius, L.; Nordstedt, C. Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J. Biol. Chem., 1997, 272, 12601-12605.
303. Gordon, D.J.; Sciarretta, K.L.; Meredith, S.C. Inhibition of betaamyloid(40) fibrillogenesis and disassembly of beta-amyloid(40) fibrils by short beta-amyloid congeners containing N-methyl amino acids at alternate residues. Biochemistry, 2001, 40, 8237-8245.
304. Hughes, E.; Burke, R.M.; Doig, A.J. Inhibition of toxicity in the beta-amyloid peptide fragment beta -(25-35) using N-methylated derivatives: a general strategy to prevent amyloid formation. J. Biol. Chem., 2000, 275, 25109-25115.
305. Akikusa, S.; Watanabe, K.I.; Horikawa, E.; Nakamura, K.; Kodaka, M.; Okuno, H.; Konakahara, T. Practical assay and molecular mechanism of aggregation inhibitors of beta-amyloid. J. Pept. Res., 2003, 61, 1-6.
306. Lowe, T.L.; Strzelec, A.; Kiessling, L.L.; Murphy, R.M. Structurefunction relationships for inhibitors of beta-amyloid toxicity containing the recognition sequence KLVFF. Biochemistry, 2001, 40, 7882-7889.
307. Pallitto, M.M.; Ghanta, J.; Heinzelman, P.; Kiessling, L.L.; Murphy, R.M. Recognition sequence design for peptidyl modulators of beta-amyloid aggregation and toxicity. Biochemistry, 1999, 38, 3570-3578.
308. Ghanta, J.; Shen, C.L.; Kiessling, L.L.; Murphy, R.M. A strategy for designing inhibitors of beta-amyloid toxicity. J. Biol. Chem., 1996, 271, 29525-29528.
309. Klein, W.L. Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int., 2002, 41, 345-352.
310. Sato, J.; Takahashi, T.; Oshima, H.; Matsumura, S.; Mihara, H. Design of peptides that form amyloid-like fibrils capturing amyloid beta1-42 peptides. Chemistry, 2007, 13, 7745-7752.
311. Nerelius, C.; Sandegren, A.; Sargsyan, H.; Raunak, R.; Leijonmarck, H.; Chatterjee, U.; Fisahn, A.; Imarisio, S.; Lomas, D.A.; Crowther, D.C.; Stromberg, R.; Johansson, J. Alpha-helix targeting reduces amyloid-beta peptide toxicity. Proc. Natl. Acad. Sci. USA, 2009, 106, 9191-9196.
312. Kallberg, Y.; Gustafsson, M.; Persson, B.; Thyberg, J.; Johansson, J. Prediction of amyloid fibril-forming proteins. J. Biol. Chem., 2001, 276, 12945-12950.
313. Petkova, A.T.; Ishii, Y.; Balbach, J.J.; Antzutkin, O.N.; Leapman, R.D.; Delaglio, F.; Tycko, R. A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl. Acad. Sci. USA, 2002, 99, 16742-16747.
314. LeVine, H.; 3rd. Small molecule inhibitors of Abeta assembly. Amyloid, 2007, 14, 185-197.
315. Verbeek, M.M.; Otte-Holler, I.; van den Born, J.; van den Heuvel, L.P.; David, G.; Wesseling, P.; de Waal, R.M. Agrin is a major heparan sulfate proteoglycan accumulating in Alzheimer's disease brain. Am. J. Pathol., 1999, 155, 2115-2125.
316. Schulz, J.G.; Megow, D.; Reszka, R.; Villringer, A.; Einhaupl, K.M.; Dirnagl, U. Evidence that glypican is a receptor mediating beta-amyloid neurotoxicity in PC12 cells. Eur. J. Neurosci., 1998, 10, 2085-2093.
317. Fraser, P.E.; Nguyen, J.T.; Chin, D.T.; Kirschner, D.A. Effects of sulfate ions on Alzheimer beta/A4 peptide assemblies: implications for amyloid fibril-proteoglycan interactions. J. Neurochem., 1992, 59, 1531-1540.
318. Kroger, S.; Schroder, J.E. Agrin in the developing CNS: new roles for a synapse organizer. News Physiol. Sci., 2002, 17, 207-212.
319. Aisen, P.S.; Saumier, D.; Briand, R.; Laurin, J.; Gervais, F.; Tremblay, P.; Garceau, D. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology, 2006, 67, 1757-1763.
320. Gervais, F.; Chalifour, R.; Garceau, D.; Kong, X.; Laurin, J.; McLaughlin, R.; Morissette, C.; Paquette, J. Glycosaminoglycan mimetics: a therapeutic approach to cerebral amyloid angiopathy. Amyloid, 2001, 8 Suppl 1, 28-35.
321. Saumier, D.; Duong, A.; Haine, D.; Garceau, D.; Sampalis, J. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study. J. Nutr. Health Aging, 2009, 13, 808-812.
322. Frederickson, C.J.; Koh, J.Y.; Bush, A.I. The neurobiology of zinc in health and disease. Nat. Rev. Neurosci., 2005, 6, 449-462.
323. Cherny, R.A.; Atwood, C.S.; Xilinas, M.E.; Gray, D.N.; Jones, W.D.; McLean, C.A.; Barnham, K.J.; Volitakis, I.; Fraser, F.W.; Kim, Y.; Huang, X.; Goldstein, L.E.; Moir, R.D.; Lim, J.T.; Beyreuther, K.; Zheng, H.; Tanzi, R.E.; Masters, C.L.; Bush, A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron, 2001, 30, 665-676.
324. Ritchie, C.W.; Bush, A.I.; Mackinnon, A.; Macfarlane, S.; Mastwyk, M.; MacGregor, L.; Kiers, L.; Cherny, R.; Li, Q.X.; Tammer, A.; Carrington, D.; Mavros, C.; Volitakis, I.; Xilinas, M.; Ames, D.; Davis, S.; Beyreuther, K.; Tanzi, R.E.; Masters, C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol., 2003, 60, 1685-1691.
325. Opazo, C.; Luza, S.; Villemagne, V.L.; Volitakis, I.; Rowe, C.; Barnham, K.J.; Strozyk, D.; Masters, C.L.; Cherny, R.A.; Bush, A.I. Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Aging Cell, 2006, 5, 69-79.
326. Adlard, P.A.; Cherny, R.A.; Finkelstein, D.I.; Gautier, E.; Robb, E.; Cortes, M.; Volitakis, I.; Liu, X.; Smith, J.P.; Perez, K.; Laughton, K.; Li, Q.X.; Charman, S.A.; Nicolazzo, J.A.; Wilkins, S.; Deleva, K.; Lynch, T.; Kok, G.; Ritchie, C.W.; Tanzi, R.E.; Cappai, R.; Masters, C.L.; Barnham, K.J.; Bush, A.I. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron, 2008, 59, 43-55.
327. Lannfelt, L.; Blennow, K.; Zetterberg, H.; Batsman, S.; Ames, D.; Harrison, J.; Masters, C.L.; Targum, S.; Bush, A.I.; Murdoch, R.; Wilson, J.; Ritchie, C.W. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol., 2008, 7, 779-786.
328. McLaurin, J.; Kierstead, M.E.; Brown, M.E.; Hawkes, C.A.; Lambermon, M.H.; Phinney, A.L.; Darabie, A.A.; Cousins, J.E.; French, J.E.; Lan, M.F.; Chen, F.; Wong, S.S.; Mount, H.T.; Fraser, P.E.; Westaway, D.; St George-Hyslop, P. Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat. Med., 2006, 12, 801-808.
329. Townsend, M.; Cleary, J.P.; Mehta, T.; Hofmeister, J.; Lesne, S.; O'Hare, E.; Walsh, D.M.; Selkoe, D.J. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers. Ann. Neurol., 2006, 60, 668-676.
330. Snow, A.; Cummings, J.; Lake, T.; Esposito, L.; Hudson, F.; Hu, Q.; Cam, J.; Aker, J. Exebryl-1: A novel small molecule drug that markedly reduces amyloid plaque load and improves memory, enters clinical trials. Alzheimers Dement 2008, 4, P2-310.
331. Hong, H.S.; Rana, S.; Barrigan, L.; Shi, A.; Zhang, Y.; Zhou, F.; Jin, L.W.; Hua, D.H. Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo. J. Neurochem., 2009, 108, 1097-1108.
332. Nakagami, Y.; Nishimura, S.; Murasugi, T.; Kaneko, I.; Meguro, M.; Marumoto, S.; Kogen, H.; Koyama, K.; Oda, T. A novel betasheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br. J. Pharmacol., 2002, 137, 676-682.
333. Walsh, D.M.; Townsend, M.; Podlisny, M.B.; Shankar, G.M.; Fadeeva, J.V.; Agnaf, O.E.; Hartley, D.M.; Selkoe, D.J. Certain inhibitors of synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomerization of natural Abeta and thereby rescue longterm potentiation. J. Neurosci., 2005, 25, 2455-2462.
334. Scopes, D.; Amijee, H.; Nerou, E.; Treherne, J.; O'Hare, E.; Jeggo, R.; Whyment, A.; Spanswick, D. SEN1269: A novel inhibitor of amyloid beta toxicity. Alzheimers Dement, 2008, 4, p2-358.
335. Lecanu, L.; Yao, W.; Teper, G.L.; Yao, Z.X.; Greeson, J.; Papadopoulos, V. Identification of naturally occurring spirostenols preventing beta-amyloid-induced neurotoxicity. Steroids, 2004, 69, 1-16.
336. SamaritanPharmaceuticals. Caprospinol (SP-233): A small molecule therapeutic indicated in Alzheimer's disease (AD). http://www.samaritanpharma.com/alzheimers_disease_cns_progra m_sp-233.asp, Assessed on December 5, 2008, 2007.
337. Baum, L.; Ng, A. Curcumin interaction with copper and iron suggests one possible mechanism of action in Alzheimer's disease animal models. J. Alzheimers Dis., 2004, 6, 367-377; discussion 443-369.
338. Frautschy, S.A.; Hu, W.; Kim, P.; Miller, S.A.; Chu, T.; Harris- White, M.E.; Cole, G.M. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol. Aging, 2001, 22, 993-1005.
339. Lim, G.P.; Chu, T.; Yang, F.; Beech, W.; Frautschy, S.A.; Cole, G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci., 2001, 21, 8370-8377.
340. Yang, F.; Lim, G.P.; Begum, A.N.; Ubeda, O.J.; Simmons, M.R.; Ambegaokar, S.S.; Chen, P.P.; Kayed, R.; Glabe, C.G.; Frautschy, S.A.; Cole, G.M. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem., 2005, 280, 5892-5901.
341. Yao, Z.; Drieu, K.; Papadopoulos, V. The Ginkgo biloba extract EGb 761 rescues the PC12 neuronal cells from beta-amyloidinduced cell death by inhibiting the formation of beta-amyloidderived diffusible neurotoxic ligands. Brain Res., 2001, 889, 181-190.
342. Ehrnhoefer, D.E.; Bieschke, J.; Boeddrich, A.; Herbst, M.; Masino, L.; Lurz, R.; Engemann, S.; Pastore, A.; Wanker, E.E. EGCG redirects amyloidogenic polypeptides into unstructured, offpathway oligomers. Nat. Struct. Mol. Biol., 2008, 15, 558-566.
343. Rezai-Zadeh, K.; Shytle, D.; Sun, N.; Mori, T.; Hou, H.; Jeanniton, D.; Ehrhart, J.; Townsend, K.; Zeng, J.; Morgan, D.; Hardy, J.; Town, T.; Tan, J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci., 2005, 25, 8807-8814.
344. Qin, X.R.; Abe, H.; Nakanishi, H. NMR and CD studies on the interaction of Alzheimer beta-amyloid peptide (12-28) with beta cyclodextrin. Biochem. Biophys. Res. Commun., 2002, 297, 1011-1015.
345. Camilleri, P.; Haskins, N.J.; Howlett, D.R. beta-Cyclodextrin interacts with the Alzheimer amyloid beta-A4 peptide. FEBS Lett., 1994, 341, 256-258.
346. Yu, J.; Bakhos, L.; Chang, L.; Holterman, M.J.; Klein, W.L.; Venton, D.L. Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers. J. Mol. Neurosci., 2002, 19, 51-55.
347. Wang, Z.; Chang, L.; Klein, W.L.; Thatcher, G.R.; Venton, D.L. Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers. J. Med. Chem., 2004, 47, 3329-3333.
348. De Felice, F.G.; Vieira, M.N.; Saraiva, L.M.; Figueroa-Villar, J.D.; Garcia-Abreu, J.; Liu, R.; Chang, L.; Klein, W.L.; Ferreira, S.T. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization. FASEB J., 2004, 18, 1366-1372.
349. Davis, T.J.; Soto-Ortega, D.D.; Kotarek, J.A.; Gonzalez-Velasquez, F.J.; Sivakumar, K.; Wu, L.; Wang, Q.; Moss, M.A. Comparative study of inhibition at multiple stages of amyloid-beta self-assembly provides mechanistic insight. Mol. Pharmacol., 2009, 76, 405-413.
350. Byeon, S.R.; Lee, J.H.; Sohn, J.H.; Kim, D.C.; Shin, K.J.; Yoo, K.H.; Mook-Jung, I.; Lee, W.K.; Kim, D.J. Bis-styrylpyridine and bis-styrylbenzene derivatives as inhibitors for Abeta fibril formation. Bioorg. Med. Chem. Lett., 2007, 17, 1466-1470.
351. Dolphin, G.T.; Chierici, S.; Ouberai, M.; Dumy, P.; Garcia, J. A multimeric quinacrine conjugate as a potential inhibitor of Alzheimer's beta-amyloid fibril formation. Chembiochem., 2008, 9, 952-963.
352. rd H.; Lipinski, W.; Sakkab, A.T.; Tasaki, Y.; Walker, L.C.; Yasunaga, T.; Ye, Y.; Zhuang, N.; Augelli-Szafran, C.E. The synthesis and structure-activity relationship of substituted N-phenyl anthranilic acid analogs as amyloid aggregation inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 654-657.
353. Saavedra, L.; Mohamed, A.; Ma, V.; Kar, S.; de Chaves, E.P. Internalization of beta-amyloid peptide by primary neurons in the absence of apolipoprotein E. J. Biol. Chem., 2007, 282, 35722-35732.